Overview

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants

Status:
RECRUITING

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), and healthy participants of Chinese and Japanese descent (Part C).

Phase:

PHASE1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

belimumab